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MaBACKGROUND Pericardial effusion (PE) is common in cancer patients, but the optimal therapeutic approach is not well
deﬁned. Percutaneous pericardiocentesis is less invasive than surgery, but its long-term effectiveness and safety have not
been well documented.
OBJECTIVES The goal of this study was to evaluate outcomes of cancer patients undergoing percutaneous
pericardiocentesis for PE and assess the procedure’s safety in patients with thrombocytopenia.
METHODS Cancer patients who underwent percutaneous pericardiocentesis for PE between November 2009 and
October 2014 at the MD Anderson Cancer Center were included. Procedure-related complications, effusion recurrence
rate, and overall survival were analyzed.
RESULTS Of 1,645 cancer patients referred for PE, 212 (13%) underwent percutaneous pericardiocentesis. The procedure
was successful in 99%of the cases, and therewere noprocedure-related deaths. Four patients hadmajor procedure-related
bleeding that did not vary by platelet count <50,000/ml or$50,000/ml (p ¼ 0.1281). Patients with catheter drainage for
3 to 5 days had the lowest recurrence rate (10%). Median overall survival was 143 days; older age (i.e., >65 years), lung
cancer, platelet count <20,000/ml, and malignant pericardial ﬂuid were independently associated with poor prognosis.
Lung cancer patients with proven malignant effusions had a signiﬁcantly shorter median 1-year survival compared with
thosewith nonmalignant effusions (16.2% vs. 49.0%, respectively; log-rank test p¼0.0101). A similar difference in 1-year
survival was not observed in patients with breast cancer (40.2% vs. 40.0%; log-rank test p ¼ 0.4170).
CONCLUSIONS Percutaneous pericardiocentesis with extended catheter drainage was safe and effective as the primary
treatment for PE in cancer patients, including in those with thrombocytopenia. Malignant PE signiﬁcantly shortened the
survival outcome of patients with lung cancer but not those with breast cancer. (J Am Coll Cardiol 2015;66:1119–28)
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ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
PE = pericardial effusion
PT = prothrombin time
RBC = red blood cell
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1120percutaneous pericardiocentesis with or
without extended catheter drainage. Scle-
rosing agents and balloon pericardiectomy
have also been used and reportedly reduce
the risk for PE recurrence.
Several studies have suggested that the
surgical method provides more deﬁnitiveprimary treatment of malignant PE compared with
pericardiocentesis (6–8); however, this approach is
associated with signiﬁcant morbidity (4,9–12). As
instruments and techniques have improved (espe-
cially the use of echography guidance for percuta-
neous and catheter-based procedures), the clinical
application of minimally invasive techniques has
often outpaced the published data regarding their
safety and efﬁcacy. The purpose of the present study
was to evaluate the outcomes of cancer patients with
PE who underwent percutaneous pericardiocentesis.SEE PAGE 1129Thrombocytopenia is a common ﬁnding in cancer
patients and traditionally has been considered a
relative contraindication to pericardiocentesis (13).
However, because there are limited data regarding
the safety of the procedure in these patients, we also
assessed the safety of pericardiocentesis in patients
with thrombocytopenia.
METHODS
This retrospective study of cancer patients undergo-
ing percutaneous pericardiocentesis for PE at The
University of Texas MD Anderson Cancer Center was
conducted from November 2009 to October 2014. The
study protocol was reviewed and approved by the
institutional review board, and a waiver of informed
consent was obtained. Patients were selected by
searching the main institutional database for hospital
discharge diagnostic codes and matching the selected
patients with records in the cardiac catheterization
laboratory database. Patients were included in the
study if they had undergone primary percutaneous
pericardiocentesis and were excluded if they had
primary surgical pericardial window placement.
PATIENT ANALYSIS. Data were collected on patient
clinical characteristics, including age, sex, type of
malignancy, prior cancer therapy (e.g., chemo-
therapy, radiation therapy), and use of anticoagulant
agents at the time of the procedure. Clinical and
echocardiographic ﬁndings of patients presenting
with PEs were also documented. These included
clinical symptoms (e.g., dyspnea, syncope, chest
pain, palpitations) and clinical signs (e.g., tachy-
cardia, hypotension, shock, presence or absenceof pulsus paradoxus). Echocardiographic ﬁndings
documented included PE size and the absence or
presence of chamber collapse, mitral and tricuspid
valve inﬂow variation on Doppler images, and inferior
vena cava size and respiratory variation. A large PE
was deﬁned as $2 cm (14). The effusion pathology
and microbiology results obtained at the time of
pericardiocentesis were also reviewed.
Patients underwent primary percutaneous pericar-
diocentesis (guided by echocardiography, computed
tomography scan, or ﬂuoroscopy) for therapeutic or
diagnostic purposes. Percutaneous pericardiocentesis
was performed by using the shortest distance to the
pericardial cavity from the subxiphoid or intercostal
space (Figure 1). In order to reduce bleeding risks,
a 5-F micropuncture kit (Micropuncture Introducer
Kit, Silhouette Transitionless Push-Plus Design, Cook
Medical, Bloomington, Indiana) was typically used
in patients with a higher risk of bleeding (15). Both
needle and catheter positions were conﬁrmed by
using saline contrast injectionwhen echocardiography
guidance was used. After accessing the pericardial
space, the needle was exchanged over a wire to a
dilator, followed by a multihole pigtail catheter. The
catheter was then sutured and afﬁxed to the chest
wall, where it was kept for several days. A sample
(80 ml) of aspirated ﬂuid was sent for pathology,
chemistry, and microbiology testing. Post-procedure
chest radiographs were performed regularly to assess
catheter position and any immediate complication
(e.g., pneumothorax). The catheter was removed
earlier if ﬂuid drainage dropped below 25 to 50 ml
with no residual effusion seen by follow-up echocar-
diography; it was rarely maintained beyond 7 days.
Any use of sclerosing agents was documented.
Recurrence of PE and its subsequent management
were reviewed. Recurrent PE was deﬁned as reac-
cumulation of pericardial ﬂuid within 3 months’
post-procedure, documented by echocardiography.
Management of such recurrence included repeated
simple percutaneous pericardiocentesis, use of scle-
rosing agents, or placement of a surgical pericardial
window.
DATA ANALYSIS. Complications (type and rate) were
reviewed and divided into major and minor cate-
gories. Procedural bleeding complications were
divided into 4 grades: minor or no bleeding (grade 1),
major bleeding requiring blood transfusion (grade 2),
major bleeding requiring emergent surgery (grade 3),
and major bleeding leading to the patient’s death
(grade 4). The source of bleeding was recorded only if
identiﬁed. The need to transfuse platelets, fresh
frozen plasma, or red blood cell (RBC) units was also
FIGURE 1 Survival in Patients With Lung and Breast Cancer
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A B
Although the presence of malignant cells in pericardial effusion (PE) in (A) lung cancer patients led to signiﬁcantly worse survival than for those without (median overall
survival: 51 days [95% conﬁdence interval (CI): 29 to 99] vs. 287 days [95% CI: 55 to not estimable]), there was no signiﬁcant survival difference in (B) patients with
breast cancer (median overall survival: 317 days [95% CI: 71 to not estimable] vs. 241 days [95% CI: 46 to 376]).
J A C C V O L . 6 6 , N O . 1 0 , 2 0 1 5 El Haddad et al.
S E P T E M B E R 8 , 2 0 1 5 : 1 1 1 9 – 2 8 Percutaneous Pericardiocentesis in Cancer
1121recorded. Patients with thrombocytopenia were
classiﬁed into 4 subgroups: <20,000/ml, 20,000/ml to
49,999/ml, 50,000/ml to 99,999/ml, and 100,000/ml to
150,000/ml. Prophylactic platelet transfusion refers to
platelet transfusion given to prevent spontaneous
bleeding. A therapeutic platelet transfusion is given
usually to patients with active bleeding or to those
with platelet levels <50,000/ml before an invasive
procedure is performed (16). The incidence of
bleeding related to pericardiocentesis and the odds
ratio of bleeding for a platelet count <50,000/ml
relative to a platelet count $50,000/ml were esti-
mated. The Fisher exact test was used to compare the
incidence of bleeding for platelet counts <50,000/ml
and $50,000/ml. Bleeding was deﬁned as a docu-
mented bleeding event related to the procedure or
transfusion of RBCs for unexplained acute anemia.
Bleeding was attributed directly to the procedure
when no other source of bleeding was identiﬁed.
Transfusions given routinely because of low hemo-
globin levels related to chemotherapy or hematologic
malignancies were excluded and not considered
associated with procedural complications.
All continuous variables were described as mean 
SD, and categorical variables were described in terms of
counts and percentages. Because patients may have
undergone >1 pericardiocentesis during the study
period, only the ﬁrst procedure was considered in the
study; the second procedure was classiﬁed as treatment
for recurrence and was excluded from further analysis.We studied overall survival, deﬁned as the time
from the date of the procedure to date of death or
last follow-up, all within 2 years’ post-procedure.
Univariate Cox proportional hazards regression
analysis was performed to assess any relationship
between clinical variables and overall survival. A
multivariable model initially included variables with
a p value <0.15; a ﬁnal multivariable model was then
chosen by using a backward elimination process. The
parameters included in this analysis were age, sex,
platelet count subgroups, tumor type, stem cell
transplantation, presence or absence of malignancy
in the PE, chest radiation within 1 year before the
procedure, clinical or echocardiographic tamponade,
PE size (<2, 2, or >2 cm), hemorrhagic tamponade,
use of blood thinners, and duration of drainage.
Hazard ratios were estimated, and 95% conﬁdence
intervals (CIs) are provided as appropriate. All
p values were considered statistically signiﬁcant
if <0.05. SAS version 9.4 (SAS Institute, Inc., Cary,
North Carolina) was used for data analysis.
RESULTS
PATIENT CHARACTERISTICS. From a total of 1,645
cancer patients with PE documented by echocardi-
ography and seen by the cardiology service, 217
patients were identiﬁed whose condition needed
drainage. Of those, 5 patients had primary surgical
pericardial window placement and were excluded
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1122from the study; 212 patients underwent percutaneous
pericardiocentesis and were analyzed.
Patient clinical characteristics are summarized in
Table 1. Lung cancer was the most common malig-
nancy (n ¼ 61 [29% of all cases]), followed by acute
myeloblastic leukemia and lymphoma. Breast cancer
was seen in 10% of the cases; the remainder
comprised cancers of the gastrointestinal tract, can-
cers of the genitourinary tract, other hematologic
disorders (acute lymphoblastic leukemia, chronic
myeloblastic leukemia, multiple myeloma, and mye-
lodysplastic syndrome), mesothelioma, osteogenic
sarcoma, thymoma, ovarian cancer, prostate cancer,
squamous cell carcinoma of the head and neck, and
adenocarcinoma of unknown origin. One hundred
eighty-six patients (88%) were exposed to chemo-
therapy, including 122 patients (58%) who received
chemotherapy within 6 weeks before pericardiocent-
esis. The most commonly used chemotherapeutic
agents were doxorubicin (30%), cyclophosphamide
(29%), and carboplatin (27%). Thirty-three patients
(16%) were receiving different types of tyrosine ki-
nase inhibitors at the time of PE diagnosis, the
most common of which were pazopanib and erlo-
tinib (n ¼ 6 each) and dasatinib and sorafenibTABLE 1 Patient Characteristics (N ¼ 212)
Age, yrs 54.9  16.4
Sex
Male 111 (52)
Female 101 (48)
Cancer type
Lung 61 (29)
Acute myeloblastic leukemia 34 (16)
Lymphoma 27 (13)
Breast 22 (10)
Gastrointestinal 16 (8)
Other 52 (25)
Chemotherapy within 6 weeks 122 (58)
Mediastinal radiation therapy
#1 yr 33 (16)
>1 yr 35 (17)
Stem cell transplantation 39 (18)
Blood thinners
Heparin derivative 76 (36)
Antiplatelet 39 (18)
Oral anticoagulant 10 (5)
Baseline abnormal coagulation proﬁle
Prothrombin time >16 s 91 (43)
Thrombocytopenia (<150,000/ml) 79 (37)
Access catheter size
5-F micropuncture kit 187 (88)
>5-F 25 (12)
Values are mean  SD or n (%).(n ¼ 3 each). Thirty-three patients (16%) received
radiation therapy to the mediastinum within 1 year
before the procedure.
Three iatrogenic effusions were the consequences
of endomyocardial biopsies for cardiomyopathy (2
cases) or a cardiac tumor biopsy (1 case). Evidence of
tamponade was seen clinically in 83 patients (39%)
and via echocardiography in 144 patients (68%). Of all
patients, 18 (8.5%) had small to moderate PE (<2 cm);
6 of them underwent pericardiocentesis for diag-
nostic purposes and 12 to manage tamponade. Of
194 patients (91.5%) with large PEs, two-thirds
had clinical and/or echocardiographic evidence of
tamponade.
Within 2 days before the procedure, 37% of
patients were taking steroids or nonsteroidal anti-
inﬂammatory drugs, and 29% of patients were
receiving antiplatelet or anticoagulant agents.
Seventy-nine patients (37%) had a low platelet level
(<150,000/ml) at the time of the procedure. Thirty-ﬁve
patients (17%) had platelet counts <50,000/ml, and 9
cases (4%) had platelet counts <10,000/ml; the lowest
level reported was 3,000/ml. All 35 patients had a
platelet transfusion to minimize bleeding risk. Post-
transfusion platelet counts, obtained within 24 h
after transfusion, demonstrated a mean platelet
count increase of 20,700/ml. Ninety-one patients
(43%) had a prothrombin time >16 s, and 20 patients
had both a platelet count <150,000/ml and a pro-
thrombin time >16 s. The highest prothrombin time
reported was 56.4 s. Eighteen patients (9%) needed
a prophylactic transfusion and/or therapeutic fresh
frozen plasma transfusion.
PROCEDURES. Our success rate for pericardiocent-
esis (percentage of patients who had successful initial
drainage of pericardial ﬂuid clinically and echo-
cardiographically) was 99%. In 2 cases, the procedure
failed; 1 necessitated surgical window placement, and
the other was clinically observed. Pericardiocentesis
was usually performed by cardiologists (91%) using
echocardiographic guidance (93%) or combined
echocardiographic and ﬂuoroscopic guidance (42%);
16 procedures (8%) were performed by interventional
radiologists with computed tomography scan guid-
ance. A subxiphoid method was used in 63% of cases
and intercostal site entry in 37%. Most patients had
extended catheter drainage for 3 to 5 days (n ¼ 119
[56%]); 40 patients (19%) required #2 days; 36 (17%)
required 6 to 7 days; 7 (3%) continued catheter
drainage >8 days; and 10 (5%) had no catheter
placement. A 5-F micropuncture kit was used in 187
patients (88%), and 36% of these patients had
thrombocytopenia.
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1123The mean initial volume of pericardial ﬂuid
drained was 590  270 ml (range 2.5 to 1,800 ml). The
most common type of initial pericardial ﬂuid aspi-
rated was macroscopically hemorrhagic (48%). One
case had initial purulent drainage secondary to lung
abscess with pneumopericardial ﬁstula. Of 52 peri-
cardial ﬂuid samples sent for viral analysis, 1 sample
came back positive for adenovirus (500 copies/ml). Of
204 samples sent for pathological evaluation, 84
(41%) were malignant with positive cytology results,
and 120 (59%) were nonmalignant.
CLINICAL OUTCOMES. Thirty-eight patients (18%)
died within 1 month after the procedure, and 130
patients (61%) died within 2 years of the procedure.
For the entire group, the median overall survival time
from the procedure date was 143 days (95% CI: 95 to
221). In a multivariable analysis model, older age (i.e.,
>65 years), lung cancer compared with lymphoma,
platelet count <20,000/ml versus $100,000/ml, and
the presence of malignant cells in the pericardial ﬂuid
were independently associated with poor prognosis
(Table 2). Median overall survival was 344 days (95%
CI: 166 to not estimable) for patients with nonmalig-
nant PE and 71 days (95% CI: 45 to 104) for patients
with malignant PE (Central Illustration). One-year
survival post-procedure was 50% for patients with
PE with no malignant cells compared with 12% for
patients with malignant effusions.
When stratiﬁed according to cancer type, patients
with lung cancer had a median overall survival time
of 95 days (95% CI: 45 to 202), whereas patients with
other cancer types had a median overall survival time
of 166 days (95% CI: 104 to 350). Lung cancer patients
with proven malignant effusions had a signiﬁcantly
shorter median overall survival compared with those
with nonmalignant effusions (24 patients [39% of
lung cancer patients]): 1-year survival estimates of
16.2% (95% CI: 5.6 to 31.6) versus 49.0% (95% CI:
26.7 to 68.0), respectively; log-rank test p value ¼
0.0101 (Figure 2A). No signiﬁcant difference was
observed in the subgroups of breast cancer patients:
1-year survival estimates of 40.2% (95% CI: 16.0 to
63.6) versus 40.0% (95% CI: 5.2 to 75.3) (log-rank test
p ¼ 0.4170) (Figure 2B). Of note, 80% of lung cancer
patients and 91% of breast cancer patients had active
disease (i.e., chemotherapy within 6 weeks or newly
diagnosed with de novo or recurrent lung or breast
cancer). As for the hematologic malignancies, only 4
of the patients with lymphoma and none of the pa-
tients with leukemia had proven/conﬁrmed malig-
nant cells in their effusion specimens.
Among 212 patients, 4 patients experienced
procedure-related bleeding; none died of bleeding
(grade 4 bleeding). Of these 4 patients with procedure-related bleeding, 2 (5.7%) of 35 had a platelet
count <50,000/ml, and 2 (1.1%) of 177 had a platelet
count $50,000/ml. The odds ratio of bleeding for a
platelet count <50,000/ml relative to $50,000/ml was
5.3. There was no strong evidence that procedure-
related bleeding differed between the <50,000/ml
platelet count group and the$50,000/ml platelet count
group (p ¼ 0.1281); however, the lack of a difference
can be explained by the lack of statistical power
to detect bleeding events of low incidence. The 2
patients with platelet counts <50,000/ml (14,000/ml
and 29,000/ml) had grade 2 bleeding and both did
well after RBC and platelet transfusions. The other 2
patients with platelet counts >50,000/ml experienced
grade 3 bleeding and underwent surgical intervention
to stop the bleeding.
Major procedural complications occurred in 5 cases
(2%): 1 patient had a liver laceration requiring emer-
gent surgical repair; 1 had an intercostal artery lacer-
ation requiring emergent cauterization; 1 developed a
pneumothorax requiring chest tube placement; and 2
cases of catheter-related infections were documented
among the 7 patients whose catheter drainage lasted
>7 days. They were treated with catheter withdrawal
and antibiotics; the ﬁrst patient fully recovered, but
the second patient was transferred to hospice care
and died several weeks later from cancer progression.
Minor procedural complications occurred in 72 pa-
tients (34%) (Table 3). Nonsustained supraventricular
tachycardia was the most common complication
(17%), with paroxysmal atrial ﬁbrillation accounting
for 60% of these arrhythmias. Pericardial catheter
occlusion occurred in 20 cases (9%).
Among the 50 patients who had either simple
pericardiocentesis without an indwelling catheter
(n ¼ 10) or <3 days’ drainage (n ¼ 40), the recurrence
rate was 23%. In contrast, longer periods of drainage
were associated with recurrence rates of 10%, 11%,
and 14% when the catheter was left in place for 3 to 5
days, 5 to 7 days, or >7 days, respectively. Overall,
26 patients (12%) had recurrent PE; 16 (62%) had
subsequent repeated pericardiocentesis. Sclerosing
agents were used in 5 of these cases (thiotepa in 4
cases and talc in 1 case). Two of these 16 patients had a
second recurrence and subsequently underwent sur-
gery. Surgical window placement was also performed
after the ﬁrst recurrence in 5 cases. The remaining
5 patients were observed clinically and recovered
without any further treatment of their effusion.
DISCUSSION
Our results found that percutaneous pericardiocent-
esis with extended catheter drainage for 3 to 5 days is
TABLE 2 Peri-Treatment Variables and Their Association With Overall Survival
Survivors
(n/N)
2-Year Kaplan-Meier
Survival Estimate (%)
Univariate Multivariable
HR 95% CI p Value HR 95% CI p Value
Age, yrs 82/212 28 1.02 1.00 1.03 0.0060 1.01 1.00 1.02 0.0473
Platelet group/ml 0.0460* <0.0001*
$100,000 64/156 31 1.00 1.00
50,000–100,000 10/21 34 1.09 0.58 2.04 0.7807 4.49 0.71 3.12 0.2880
20,000–50,000 6/15 31 1.28 0.65 2.54 0.4774 1.58 0.78 3.23 0.2050
<20,000 2/20 5 2.06 1.24 3.42 0.0051 1.49 2.37 8.52 <0.0001
Male
Yes 48/111 36 0.89 0.63 1.25 0.4990
No 34/101 20 1.00
Tumor type 0.0040* 0.0121*
Lung cancer 20/61 21 1.00 1.00
Breast cancer 7/22 23 0.71 0.40 1.29 0.2650 0.55 0.30 1.02 0.0581
Lymphoma 20/27 67 0.23 0.11 0.52 0.0004 0.27 0.11 0.68 0.0053
Other 35/102 24 0.89 0.60 1.32 0.5600 0.89 0.57 1.39 0.6124
Stem cell transplantation
Yes 21/39 49 0.63 0.38 1.03 0.0650
No 61/173 24 1.00
Malignant cells in effusion
Yes 21/84 12 2.10 1.47 3.00 <0.0001 2.71 1.73 4.24 <0.0001
No 60/120 41 1.00 1.00
Chest radiation within 1 yr
Yes 12/33 24 1.31 0.82 2.09 0.2620
No 70/179 29 1.00
Clinical tamponade
Yes 26/82 24 1.38 0.98 1.96 0.0670
No 56/130 31 1.00
Echocardiographic tamponade
Yes 52/144 25 1.29 0.89 1.89 0.1820
No 30/68 34 1.00
Pericardial effusion size, cm
<2 11/18 52 1.89 0.88 4.06 0.1020
$2 71/194 26 1.00
Macroscopic ﬁndings
Hemorrhagic 40/102 31 1.02 0.72 1.44 0.9070
Nonhemorrhagic 42/110 26 1.00
Blood thinner usage
Yes 41/107 30 0.84 0.59 1.18 0.3080
No 41/105 27 1.00
Drainage duration, days 0.0198* 0.0128*
#2 16/50 25 1.00 1.00
3–5 55/119 33 0.70 0.46 1.06 0.0900 0.59 0.37 0.94 0.0268
$6 11/43 18 1.25 0.77 2.03 0.3690 1.08 0.63 1.86 0.7770
*Overall signiﬁcance of the parameter. p values <0.05 are in bold.
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
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1124an effective treatment modality with a low recurrence
rate. The low complication rates that we observed
showed that the procedure is well tolerated and safe,
even in patients with thrombocytopenia. In addition,
we found that malignant PE seems to signiﬁcantly
affect the survival outcome of patients with lung
cancer but not those with breast cancer.
Previously published data showed that surgical
approaches (pericardial window, pericardioperitonealshunt creation, and/or pericardiectomy) are associ-
ated with the highest success rate, ranging from 87%
(17) to 100% (18), with a complication rate of 4.7%
and rare mortality (1). In contrast, Jama et al. (1) re-
ported that percutaneous pericardiocentesis with or
without extended catheter drainage had an overall
low success rate of 60%, and many patients required
further intervention for effusion recurrence. They
also noted a high procedure-related complication
CENTRAL ILLUSTRATION Pericardiocentesis in Cancer Patients: Overall Survival Based on Presence of
Malignant Cells in PE
El Haddad, D. et al. J Am Coll Cardiol. 2015; 66(10):1119–28.
As seen in the Kaplan-Meier curve for the entire cohort, patients without malignant cells in pericardial effusion (PE) survived signiﬁcantly
longer than those with malignant cells: 344 days (95% conﬁdence interval: 166 to not estimable) versus 71 days (95% conﬁdence interval:
45 to 104).
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1125rate (8%). Although administration of sclerosing
agents after pericardiocentesis was associated with
an overall higher success rate (88%), the use of
these agents was linked to a higher rate of compli-
cations and morbidities (20%). Our percutaneous
pericardiocentesis success rate of 99%, low recur-
rence rate of 12%, and acceptable major complica-
tions rate of 2.5% all compare favorably with those of
surgery.
CLINICAL CHARACTERISTICS. In our institution,
lung cancer was the most common malignancy asso-
ciated with PE, followed by hematologic malig-
nancies, including leukemia and lymphoma; these
outcomes are similar to ﬁndings of other studies
(4,11,19). Unlike previously published data (4,10,11),
however, breast cancer was responsible for only 10%of PEs in our patient population. These ﬁndings are
possibly related to referral pattern (a very high
number of leukemia and lymphoma patients are
treated at our institution).
The mechanism of effusion was proven to be
related to direct cancer involvement of the pericar-
dium in only 41% of cases. Beyond these, 4 (2%)
patients had infectious etiologies (2 bacterial, 1 viral,
and 1 fungal). PE etiology was undetermined in
the remaining cases (57%). It has been suggested
that the etiologic mechanism of nonneoplastic
and noninfectious effusions in cancer patients is
related to obstruction of the mediastinal lym-
phatic system by tumor inﬁltration or radiotherapy-
induced ﬁbrosis. Other suggested mechanisms
include inﬂammation or ﬂuid retention triggered by
FIGURE 2 Left Ventricle in Short Axis Access Site Selection for Percutaneous Pericardiocentesis
Access site selection for percutaneous pericardiocentesis is based on the detection of the shortest distance to the largest ﬂuid pocket within the pericardial space
detected by echocardiography. This site selection can be achieved after careful bedside scanning from multiple directions. Needle and catheter insertion are performed
while avoiding the intercostal and internal mammary artery structures. (A) The anterior view of the rib cage with the internal mammary arteries and intercostal arteries in
red and pericardial ﬂuid in yellow. The small green squaresmark the location of the safe access sites. (B) Sample of short-axis echocardiographic views to help select the
shortest distance to the largest ﬂuid pocket. (C) The needle and catheter insertion site performed while avoiding the intercostal and the internal mammary arteries.
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1126certain chemotherapies (e.g., anthracyclines, dasa-
tinib) (20–22).
Procedural indications included symptomatic PE
with overt or impending tamponade (72%), largeTABLE 3 Complications Related to Percutaneous
Pericardiocentesis
Minor Nonsustained supraventricular tachycardia 37 (17.0)
Pericardial catheter occlusion 20 (9.0)
Vasovagal response 7 (3.0)
Ventricular tachycardia 6 (3.0)
Small pneumothorax (on radiograph) 1 (0.5)
Transient chamber entry 1 (0.5)
Major Bacteremia due to catheter placement 2 (1.0)
Intercostal artery laceration requiring surgery 1 (0.5)
Pneumothorax requiring chest tube placement 1 (0.5)
Liver laceration requiring surgery 1 (0.5)
Values are n (%).asymptomatic effusions (25%), and need for tissue
diagnosis to guide cancer management (3%). Thus,
most of the procedures were performed under emer-
gent circumstances. Draining large asymptomatic PE
is part of the clinical practice algorithm at our cancer
center and is based on clinical experience, and it is
extrapolated from published data (23) showing that
up to one-third of large asymptomatic PEs can prog-
ress into tamponade without earlier symptoms. We
commonly observed this outcome in our patient
population, in whom signiﬁcant ﬂuid shift often oc-
curs with cancer therapy.
PROCEDURE-RELATED COMPLICATIONS. Similar to
the ﬁndings of Lindenberger et al. (24), supraven-
tricular arrhythmia was the most common procedure-
related complication. This complication is likely
related to mechanical irritation or inﬂammation trig-
gered by the draining catheter. The 2 catheter-related
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Percutaneous pericardiocentesis with continuous
drainage for 3 to 5 days is generally a safe and effective strategy
for PE management in patients with cancer, even when
thrombocytopenia is present.
TRANSLATIONAL OUTLOOK: Further studies are needed to
assess the safety and efﬁcacy of continuing systemic anticoag-
ulant therapy during extended catheter drainage of PE in
patients with cancer, given the concurrent risk of venous
thromboembolism.
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1127infections observed were due to prolonged catheter
placement (>7 days). Overall, 79 (37%) patients had
thrombocytopenia (platelet counts <150,000/ml),
including 35 (17%) patients with severe thrombocy-
topenia (platelet counts #50,000/ml). Following
the standard transfusion guidelines (16,25–27), all
35 patients had platelet transfusions before, during,
or immediately after pericardiocentesis. No major
bleeding complications requiring surgery were
noted in these patients; 2 other patients with platelet
counts of 87,000/ml and 205,000/ml experienced
grade 3 bleeding. Although the low number of
bleeding events did not allow meaningful com-
parison between the different platelet sub-
groups, it is clinically important to note the low
incidence of bleeding complications in those with
thrombocytopenia.
Recurrence rates vary according to type of proce-
dure and duration of follow-up. Simple peri-
cardiocentesis without pericardial drainage has been
shown to be associated with the highest rate of
effusion recurrence, ranging from 33% to 55%
(4,10,24), whereas extended catheter drainage is
reportedly associated with a recurrence rate of 13% to
45% (1,4,28). In contrast, chemical pericardiodesis
was associated with a recurrence rate of 12% but was
responsible for a much higher complication rate
(21%). The surgical method has shown the best
overall recurrence rate (7%) reported thus far (1).
Of our patients, 95% had extended catheter
drainage, and 5% had simple pericardiocentesis
without any drain placement. Of those with no
extended drainage, 23% had recurrence, in contrast
to the lowest recurrence rate (10%) observed when the
draining catheter was kept in place for 3 to 5 days.
Thus, a catheter drainage duration of 3 to 5 days seems
ideal, with optimal efﬁcacy and lowest risk for peri-
cardial infection. In cases of recurrence, a more
deﬁnitive therapy is usually needed, such as repeated
pericardiocentesis; of the 26 patients with recurrent
PE in our study, 62% had malignant PE.
Thirty-eight patients died within 30 days of the
procedure, but their deaths were related to cancer
disease progression or other severe comorbidities
(e.g., sepsis, pulmonary embolism, multiple organ
failure). No procedure-related deaths were reported.
The overall median survival of the cohort was 143
days (95% CI: 95 to 221), and 130 patients died within
2 years of the procedure. Patients with malignant
cells in their effusion specimens reportedly have
shorter overall survival compared with patients
with nonmalignant ﬁndings (29). However, our data
suggest that this observation varies according to typeof malignancy. The presence of pathologically proven
malignant effusion seemed to signiﬁcantly affect the
survival of patients with lung cancer but not those
with breast cancer. This difference was observed
despite the fact that breast cancer was associated
with a higher incidence (76%) of malignant effusions
than was lung cancer (61%).
STUDY LIMITATIONS. Being a retrospective chart re-
view, the choice of method and entry site, imaging
guidance, and placement of catheter for extended
drainage were all dependent on the operator and the
patient’s general status (possible selection bias). Our
patient population’s initial performance status could
not be obtained from the data collected, and whether
patients experienced a beneﬁt of symptom relief or
an improved short-term quality of life after peri-
cardiocentesis could not be measured, especially in
those with end-stage tumors.
CONCLUSIONS
Percutaneous pericardiocentesis with extended cath-
eter drainage, as the primary treatment of PE in
cancer patients, was safe and effective even in those
with thrombocytopenia. It was associated with an
acceptable recurrence rate, and our data suggest that
catheter drainage for 3 to 5 days is associated with
the most optimal efﬁcacy/risk ratio. The presence of
proven malignant cells in PE seemed to signiﬁcantly
affect the survival of patients with lung cancer but
not those with breast cancer.
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